BCL2L1 and hematologic disorder: Therefore, targeting BCL-XL with DT2216 has been shown as a promising safe and effective therapeutic strategy in BCL-XL–dependent hematologic malignancies as a monotherapy, as well as in multiple BCL-XL-upregulated solid tumors, when combined with chemotherapeutic agents (20–23).